PPD, Inc. (PPD)
Stock Price:
$32.88 USD
-0.27 (-0.81%)
Updated Oct 30, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
11.49B |
| Revenue (ttm) |
4.36B |
| Net Income (ttm) |
53.83M |
| Shares Out |
349.57M |
| EPS (ttm) |
0.16 |
| PE Ratio |
205.50 |
| Forward PE |
24.63 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 30, 2020 |
| Last Price |
$32.88 |
| Previous Close |
$33.15 |
| Change ($) |
-0.27 |
| Change (%) |
-0.81% |
| Day's Open |
33.15 |
| Day's Range |
32.12 - 33.34 |
| Day's Volume |
1,690,518 |
| 52-Week Range |
10.61 - 37.51 |
More Stats
| Market Cap |
11.49B |
| Enterprise Value |
15.14B |
| Earnings Date (est) |
Mar 10, 2021 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
349.57M |
| Float |
113.94M |
| EPS (basic) |
0.16 |
| EPS (diluted) |
0.16 |
| FCF / Share |
0.67 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
0.49% |
| FCF Yield |
2.04% |
| Payout Ratio |
n/a |
| Shares Short |
1.82M |
| Short Ratio |
0.40 |
| Short % of Float |
1.60% |
| Beta |
n/a |
| PE Ratio |
205.50 |
| Forward PE |
24.63 |
| P/FCF Ratio |
48.96 |
| PS Ratio |
2.63 |
| PB Ratio |
n/a |
| Revenue |
4.36B |
| Operating Income |
454.71M |
| Net Income |
53.83M |
| Free Cash Flow |
234.74M |
| Net Cash |
-3.65B |
| Net Cash / Share |
-10.44 |
| Gross Margin |
61.31% |
| Operating Margin |
10.42% |
| Profit Margin |
1.20% |
| FCF Margin |
5.38% |
| ROA |
4.74% |
| ROE |
n/a |
| ROIC |
6.20% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (17)
| Buy |
15 |
| Overweight |
1 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$39.93*
(21.44% upside)
Low
35.0
Current: $32.88
High
42.0
Target: 39.93
*Average 12-month price target from 15 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|
| Revenue | 4,031 | 3,749 | 3,001 | 2,680 |
| Revenue Growth | 7.52% | 24.92% | 12% | - |
| Gross Profit | 1,622 | 1,474 | 1,464 | 1,293 |
| Operating Income | 417 | 373 | 218 | 286 |
| Net Income | 47.82 | 104 | 296 | 183 |
| Shares Outstanding | 279 | 279 | 291 | 312 |
| Earnings Per Share | 0.19 | 0.34 | 0.68 | 0.58 |
| EPS Growth | -44.12% | -50% | 17.24% | - |
| Operating Cash Flow | 433 | 423 | 359 | 408 |
| Capital Expenditures | -126 | -116 | -105 | -90.22 |
| Free Cash Flow | 307 | 307 | 254 | 318 |
| Cash & Equivalents | 345 | 553 | 419 | - |
| Total Debt | 5,844 | 4,796 | 4,822 | - |
| Net Cash / Debt | -5,498 | -4,243 | -4,403 | - |
| Assets | 5,556 | 5,489 | 5,445 | - |
| Liabilities | 8,224 | 6,987 | 6,915 | - |
| Book Value | -2,698 | -1,522 | -1,492 | - |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
PPD, Inc. |
| Country |
United States |
| Employees |
24,000 |
| CEO |
David S. Simmons |
Stock Information
| Ticker Symbol |
PPD |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Drug Manufacturers—Specialty & Generic |
| Unique Identifier |
NASDAQ: PPD |
| IPO Date |
February 6, 2020 |
Description
PPD provides drug development services to the biopharmaceutical industry worldwide. The company operates through Clinical Development Services and Laboratory Services segments. It offers clinical development services, including product development and consulting, early development, Phases II-IV clinical trial management, accelerated enrollment, peri- and post-approval, and medical communications services. The company also provides laboratory services comprising bioanalytical, biomarker, vaccine science, good manufacturing practice, and central laboratory services. It serves pharmaceutical, biotechnology, medical device, and government organizations, as well as other industry participants. The company was founded in 1985 and is headquartered in Wilmington, North Carolina.